Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

STATs in cancer inflammation and immunity: a leading role for STAT3.

Yu H, Pardoll D, Jove R.

Nat Rev Cancer. 2009 Nov;9(11):798-809. doi: 10.1038/nrc2734. Review.

2.

Stat3: linking inflammation to (gastrointestinal) tumourigenesis.

Ernst M, Putoczki TL.

Clin Exp Pharmacol Physiol. 2012 Aug;39(8):711-8. doi: 10.1111/j.1440-1681.2011.05659.x. Review.

PMID:
22211709
3.

Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.

Lai SY, Johnson FM.

Drug Resist Updat. 2010 Jun;13(3):67-78. doi: 10.1016/j.drup.2010.04.001. Epub 2010 May 14. Review.

PMID:
20471303
4.

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

Yu H, Kortylewski M, Pardoll D.

Nat Rev Immunol. 2007 Jan;7(1):41-51. Review.

PMID:
17186030
5.

IL-2 activation of STAT5 enhances production of IL-10 from human cytotoxic regulatory T cells, HOZOT.

Tsuji-Takayama K, Suzuki M, Yamamoto M, Harashima A, Okochi A, Otani T, Inoue T, Sugimoto A, Motoda R, Yamasaki F, Nakamura S, Kibata M.

Exp Hematol. 2008 Feb;36(2):181-92. Epub 2007 Nov 26.

PMID:
18023521
6.

JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.

Slattery ML, Lundgreen A, Kadlubar SA, Bondurant KL, Wolff RK.

Mol Carcinog. 2013 Feb;52(2):155-66. doi: 10.1002/mc.21841. Epub 2011 Nov 28.

7.

IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis.

Bollrath J, Greten FR.

EMBO Rep. 2009 Dec;10(12):1314-9. doi: 10.1038/embor.2009.243. Epub 2009 Nov 6. Review.

8.

Mutations leading to constitutive active gp130/JAK1/STAT3 pathway.

Pilati C, Zucman-Rossi J.

Cytokine Growth Factor Rev. 2015 Oct;26(5):499-506. doi: 10.1016/j.cytogfr.2015.07.010. Epub 2015 Jul 3. Review.

PMID:
26188635
9.

JAK2 inhibitor blocks the inflammation and growth of esophageal squamous cell carcinoma in vitro through the JAK/STAT3 pathway.

Fang J, Chu L, Li C, Chen Y, Hu F, Zhang X, Zhao H, Liu Z, Xu Q.

Oncol Rep. 2015 Jan;33(1):494-502. doi: 10.3892/or.2014.3609. Epub 2014 Nov 14.

PMID:
25405520
10.

An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT.

Fujitani Y, Hibi M, Fukada T, Takahashi-Tezuka M, Yoshida H, Yamaguchi T, Sugiyama K, Yamanaka Y, Nakajima K, Hirano T.

Oncogene. 1997 Feb 20;14(7):751-61.

11.

STAT proteins as novel targets for cancer drug discovery.

Turkson J.

Expert Opin Ther Targets. 2004 Oct;8(5):409-22. Review.

PMID:
15469392
12.

JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin.

Wang X, Liu Q, Ihsan A, Huang L, Dai M, Hao H, Cheng G, Liu Z, Wang Y, Yuan Z.

Toxicol Sci. 2012 Jun;127(2):412-24. doi: 10.1093/toxsci/kfs106. Epub 2012 Mar 27.

PMID:
22454431
13.

STAT5 in Cancer and Immunity.

Rani A, Murphy JJ.

J Interferon Cytokine Res. 2016 Apr;36(4):226-37. doi: 10.1089/jir.2015.0054. Epub 2015 Dec 30. Review.

PMID:
26716518
14.

STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease.

Sikorski K, Czerwoniec A, Bujnicki JM, Wesoly J, Bluyssen HA.

Cytokine Growth Factor Rev. 2011 Aug;22(4):211-9. doi: 10.1016/j.cytogfr.2011.06.003. Epub 2011 Jul 12. Review.

PMID:
21752694
15.

IL-6 activates STAT5 in T cells.

Tormo AJ, Letellier MC, Sharma M, Elson G, Crabé S, Gauchat JF.

Cytokine. 2012 Nov;60(2):575-82. doi: 10.1016/j.cyto.2012.07.002. Epub 2012 Jul 31.

PMID:
22854263
16.

Sleep loss activates cellular inflammation and signal transducer and activator of transcription (STAT) family proteins in humans.

Irwin MR, Witarama T, Caudill M, Olmstead R, Breen EC.

Brain Behav Immun. 2015 Jul;47:86-92. doi: 10.1016/j.bbi.2014.09.017. Epub 2014 Oct 17.

17.

STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice.

Ernst M, Najdovska M, Grail D, Lundgren-May T, Buchert M, Tye H, Matthews VB, Armes J, Bhathal PS, Hughes NR, Marcusson EG, Karras JG, Na S, Sedgwick JD, Hertzog PJ, Jenkins BJ.

J Clin Invest. 2008 May;118(5):1727-38. doi: 10.1172/JCI34944.

19.

"Activated" STAT proteins: a paradoxical consequence of inhibited JAK-STAT signaling in cytomegalovirus-infected cells.

Trilling M, Le VT, Rashidi-Alavijeh J, Katschinski B, Scheller J, Rose-John S, Androsiac GE, Jonjic S, Poli V, Pfeffer K, Hengel H.

J Immunol. 2014 Jan 1;192(1):447-58. doi: 10.4049/jimmunol.1203516. Epub 2013 Dec 6.

20.

Supplemental Content

Support Center